Human chorionic gonadotrophin (HCG) and/or alpha-fetoprotein (AFP) are elevated in the serum of about 80% of patients with non-seminomatous germ cell tumours (NSGCT) (Newlands, et al., 1976; Norgaard-Pederson et al., 1984; Javadpour, 1979) . The prognostic value of tumour markers in patients wtih germ cell tumours was first demonstrated in 1980 (Germa-Luck et al., 1980 ). An initial HCG >50,000 i.u. - ' and/or an AFP >500 ku 1`were shown to be the most important indicators of failure to achieve complete remission following chemotherapy. Later studies have confirmed the prognostic significance of HCG and AFP values with the largest studies using HCG levels of > 1,000 i.u. I`or > 5,000 i.u. 1' as indicators of poor survival (MRC Working Party on Testicular Tumours, 1985; Stoter et al., 1987; Bosl et al., 1983) . Tumour Weeks to high risk Figure 1 The percentage of patients whose markers could potentially reach the poor prognosis level (HCG > 1,000 i.u. 1`and/or AFP>500ku 1-') within 1-6 weeks.
Discussion
Serial measurements of AFP and HCG are of great value in assessing response to chemotherapy, detecting relapse and enabling therapy to commence before patients with NSGCT are assigned to a poor prognosis (Newlands et al., 1976; Norgaard-Pedersen et al., 1984; Javadpour, 1979; GermaLuck et al., 1980 ; MRC Working Party on Testicular Tumours, 1985; Stoter et al., 1987; Bosl et al., 1983; Crawford et al., 1988) . However, there is no general agreement between centres concerning the frequency of marker estimation during treatment and follow-up. Our results suggest that if only monthly marker estimations are performed, 16 of 64 (25%) patients could have levels within the poor prognostic range by the time they start chemotherapy at 6 weeks. The additional 2 week delay occurs because most centers do not start treatment on the basis of one raised result and therefore require repeat tests. Even weekly marker estimations could result in three of 64 (4.7%) patients having poor prognosis marker levels within 3 weeks. At least two points need to be considered when enterpreting the data. Firstly our calculation of potential marker doubling time is based on the assumption of an expontial rate of marker rise. In fact many patients had marker rises which were initially rapid, but often briefly plateaued within a good prognosis range. This provides a potential 'breathing space' to institute therapy, and makes us confident in suggesting weekly rather than more frequent marker estimations. The observation of one patient having 9.2 doublings in 31 days suggests that the potential doubling time that we have calculated can indeed occur.
Secondly the worst pre-cisplatin patients took only 5-8 days to enter a poor prognosis category whereas the worst cisplatin failure or stage 1 follow-up patients needed 40-70 days. This difference could be attributed to the lower response rates with non-cisplatin therapy. Perhaps the most likely explanation is the smaller number of patients studied in both the stage 1 follow-ups and the cisplatin failure groups, i.e. if enough stage 1 follow-ups had been studied some may have had marker rises as fast as seen in the pre-cisplatin era. We therefore still regard weekly marker estimation as sufficient for stage 1 follow-up patients, at least during the first 6 months, since most relapses occur within this time (Crawford et al., 1988; Freedman et al., 1987) . For posttreatment patients, weekly marker measurements are similarly appropriate, although the best chance of cure occurs with the first treatment cycle and not at relapse. Corroborative evidence that our recommendation of weekly marker levels is correct comes from a recent MRC study (MRC Working Party on Testicular Tumours, 1985) . Of 259 patients with stage 1 disease on surveillance, three died. One of these had an HCG level of over 30,000 i.u. 1' on relapse, but only had tumour marker levels performed once every 4 weeks (W.G. Jones, personal communication). A summary of our recommendations for frequency of tumour marker measurements in NSGCT is provided in Table II . Clearly, performing more frequent marker tests incurs extra cost. Using the automated follow-up service at the Charing Cross Hospital, the overall costs of an HCG and AFP assay are £6. The cost of marker analysis for 400 stage 1 surveillance patients over 2 years would be £57,600 if performed monthly and £91,200 if performed weekly for 26 weeks, then monthly for 1.5 years; a difference of £33,600. Approximately 100 of these 400 patients would be expected to relapse (Crawford et al., 1988; Freedman et al., 1987) . Eighty of these patients would be marker producers of whom as many as 12.5% could develop poor prognostic markers within 4 weeks (Figure 1 ). There is at least a 10% survival difference between patients with good and poor prognosis marker values (Germa-Luck et al., 1980; MRC Working Party on Testicular Tumours, 1985; Stoter et al., 1987; Bosl et al., 1983; Newlands et al., 1986) . Initial weekly marker estimations would therefore be expected to result in at least an extra 1:400 patients becoming long-term survivers for only an extra £33,600. This, in our view, is very cost-effective.
The inconvenience of more frequent blood tests can be reduced by using an automated follow up scheme such as that developed at Charing Cross Hospital (Rustin, 1986) . Returnable boxes are sent to the patient's home address with a request for them to attend the nearest pathology department by the specified date, and serum is sent in the box to the assay laboratory.
It is hoped that better marker follow up will reduce the likelihood of patients on surveillance for NSGCT falling into a poor prognosis category and enable less toxic therapy to be utilised at an earlier date.
